Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V160 CMV Vaccine in Healthy Women
NCT03486834Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2018
- Primary completion
- Oct 2020
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
A Phase 2 trial of V160 in cytomegalovirus infection (CMV), sponsored by Merck & Co.. Started Apr 2018; status: completed.
02
Drugs
V160
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03486834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486834.